REYE SYNDROME REVISED WARNING OPPOSED BY P&G, ASPIRIN FOUNDATION
This article was originally published in The Tan Sheet
Executive Summary
REYE SYNDROME REVISED WARNING OPPOSED BY P&G, ASPIRIN FOUNDATION of America in comments on FDA's Oct. 20 proposal to revise the Reye syndrome warning on aspirin and to require the warning on both aspirin and non-aspirin salicylate products. The two commenters objected to the proposal, in part, on the grounds that the revised warning, which is based on the voluntary warning used for Procter & Gamble's bismuth subsalicylate product, Pepto- Bismol, does not take into consideration the different conditions for which aspirin and other salicylate products are used.